Switch theme
Sign up to access all valuation multiples
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
1996
1.3K+
LTM Revenue $3.0B
LTM EBITDA $1.6B
$11.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
United Therapeutics has a last 12-month revenue (LTM) of $3.0B and a last 12-month EBITDA of $1.6B.
In the most recent fiscal year, United Therapeutics achieved revenue of $2.9B and an EBITDA of $1.7B.
United Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See United Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0B | XXX | $2.9B | XXX | XXX | XXX |
| Gross Profit | $2.7B | XXX | $2.6B | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 89% | XXX | XXX | XXX |
| EBITDA | $1.6B | XXX | $1.7B | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 57% | XXX | XXX | XXX |
| EBIT | $1.5B | XXX | $1.4B | XXX | XXX | XXX |
| EBIT Margin | 49% | XXX | 50% | XXX | XXX | XXX |
| Net Profit | $1.3B | XXX | $1.2B | XXX | XXX | XXX |
| Net Margin | 42% | XXX | 42% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, United Therapeutics's stock price is $318.
United Therapeutics has current market cap of $14.4B, and EV of $11.2B.
See United Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.2B | $14.4B | XXX | XXX | XXX | XXX | $25.97 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, United Therapeutics has market cap of $14.4B and EV of $11.2B.
United Therapeutics's trades at 3.9x EV/Revenue multiple, and 6.8x EV/EBITDA.
Equity research analysts estimate United Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
United Therapeutics has a P/E ratio of 11.4x.
See valuation multiples for United Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $14.4B | XXX | $14.4B | XXX | XXX | XXX |
| EV (current) | $11.2B | XXX | $11.2B | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | 7.0x | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBIT | 7.5x | XXX | 7.8x | XXX | XXX | XXX |
| EV/Gross Profit | 4.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 11.4x | XXX | 12.0x | XXX | XXX | XXX |
| EV/FCF | 10.9x | XXX | 10.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialUnited Therapeutics's last 12 month revenue growth is 10%
United Therapeutics's revenue per employee in the last FY averaged $2.2M, while opex per employee averaged $0.9M for the same period.
United Therapeutics's rule of 40 is 69% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
United Therapeutics's rule of X is 77% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for United Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 57% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | 69% | XXX | 67% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 77% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
United Therapeutics acquired XXX companies to date.
Last acquisition by United Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . United Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was United Therapeutics founded? | United Therapeutics was founded in 1996. |
| Where is United Therapeutics headquartered? | United Therapeutics is headquartered in United States of America. |
| How many employees does United Therapeutics have? | As of today, United Therapeutics has 1.3K+ employees. |
| Who is the CEO of United Therapeutics? | United Therapeutics's CEO is Dr. Martine A. Rothblatt, J.D.,M.B.A.,PhD. |
| Is United Therapeutics publicy listed? | Yes, United Therapeutics is a public company listed on NAS. |
| What is the stock symbol of United Therapeutics? | United Therapeutics trades under UTHR ticker. |
| When did United Therapeutics go public? | United Therapeutics went public in 1999. |
| Who are competitors of United Therapeutics? | Similar companies to United Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of United Therapeutics? | United Therapeutics's current market cap is $14.4B |
| What is the current revenue of United Therapeutics? | United Therapeutics's last 12 months revenue is $3.0B. |
| What is the current revenue growth of United Therapeutics? | United Therapeutics revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of United Therapeutics? | Current revenue multiple of United Therapeutics is 3.7x. |
| Is United Therapeutics profitable? | Yes, United Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of United Therapeutics? | United Therapeutics's last 12 months EBITDA is $1.6B. |
| What is United Therapeutics's EBITDA margin? | United Therapeutics's last 12 months EBITDA margin is 53%. |
| What is the current EV/EBITDA multiple of United Therapeutics? | Current EBITDA multiple of United Therapeutics is 7.0x. |
| What is the current FCF of United Therapeutics? | United Therapeutics's last 12 months FCF is $1.0B. |
| What is United Therapeutics's FCF margin? | United Therapeutics's last 12 months FCF margin is 34%. |
| What is the current EV/FCF multiple of United Therapeutics? | Current FCF multiple of United Therapeutics is 10.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
